Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00213148 · ClinicalTrials.gov registry record · Phase 2

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

A Phase 2 study, sponsored by EMD Serono.

Completed
Registry status
Phase 2
Development phase
271
Enrollment target

NCT00213148: Completed Phase 2 study, sponsored by EMD Serono.

NCT00213148 is a Phase 2 study that has completed, run by EMD Serono. The registered enrollment target is 271 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (104% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00213148, a Phase 2 study, has completed, sponsored by EMD Serono.

COMPLETED
Registry status
Phase 2
Development phase
271 participants
Enrollment target

Study Summary

The purpose of this study is to investigate and compare the safety and efficacy of various doses of the aromatase inhibitor (anastrozole) versus clomiphene citrate in stimulating follicular growth and ovulation in infertile women with ovulatory dysfunction.

Primary Outcome

Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron \[P4\] level greater than or equal to \[\>=\] 10 nanogram per milliliter \[ng/mL\] and/or pregnancy).

Interventions

  • DRUG Anastrozole 1 mg
  • DRUG Anastrozole 5 mg
  • DRUG Anastrozole 10 mg
  • DRUG Clomiphene Citrate 50 mg
  • DRUG Clomiphene Citrate 100 mg

Trial Details

FieldValue
Enrollment Target 271 participants
Start Date 2005-03-10
Est. Completion 2007-12-12
Phase Phase 2
EMD Serono

71 total trials

What the finished NCT00213148 record still lists

NCT00213148 is an interventional study that assigns participants to a tested intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (104% higher).

The record links to 0 conditions, and to 5 interventions - of which Anastrozole 1 mg is the first listed.

NCT00213148 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00213148 about?

NCT00213148 is a clinical study titled "Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction". The purpose of this study is to investigate and compare the safety and efficacy of various doses of the aromatase inhibitor (anastrozole) versus clomiphene citrate in stimulating follicular growth and ovulation in infertile women with ovulatory dysfunction.

What is the current status of trial NCT00213148?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 271 participants. The study started on 2005-03-10. Estimated completion is 2007-12-12.

What interventions are being tested in trial NCT00213148?

The interventions under investigation include: Anastrozole 1 mg (DRUG), Anastrozole 5 mg (DRUG), Anastrozole 10 mg (DRUG), Clomiphene Citrate 50 mg (DRUG), Clomiphene Citrate 100 mg (DRUG).

Who is sponsoring clinical trial NCT00213148?

This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00213148's enrollment target sits among peer trials

271 205th of 2000 higher than 1,796 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03609216 · 271 participants · Phase 2

    Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

  • NCT02468024 · 272 participants · Phase 3

    JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

  • NCT05519449 · 272 participants · Phase 1

    Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  • NCT06035939 · 272 participants · NA

    SMYLS Multi-site Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00213148, the US trial registry maintained by the National Library of Medicine. NCT00213148 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.